Genentech, a part of the Roche Group (RHHBY), reported that the newly obtained long-term data for its product, Vabysmo, showcased sustainable retinal drying and visual enhancement in cases of Retinal Vein Occlusion or RVO.
Genentech revealed the latest 72-week data derived from two international Phase III studies, BALATON and COMINO. Both examined Vabysmo, also known as faricimab-svoa, in the treatment of macular edema due to branch retinal vein occlusion and central retinal vein occlusion (BRVO and CRVO).
Compared to traditional RVO treatments, typically administered every one to two months, the data demonstrated that approximately 60% of Vabysmo recipients in the BALATON study, and up to 48% in the COMINO study, were able to extend their treatment intervals to three or four months apart, according to Genentech.
Additionally, the visual improvements and significant retinal drying achieved during the initial 24 weeks of the trials were maintained by the patients for more than one year.
Vabysmo was well received in both studies, displaying a safety profile that was in line with previous studies.
Retinal drying is a crucial clinical measure as excessive fluid accumulation in the back of the eye can result in distorted and blurry vision.
The company reported that the study's results will be virtually showcased at the Angiogenesis, Exudation, and Degeneration 2024 conference, coordinated by the Bascom Palmer Eye Institute in Florida, on February 3.
Vabysmo has been authorized in over 90 countries globally to treat wet age-related macular degeneration and diabetic macular edema patients. To date, more than 2.5 million doses have been distributed worldwide.
In October 2023, the U.S. Food and Drug Administration approved Vabysmo for the treatment of macular edema subsequent to RVO.
Retinal Vein Occlusion ranks as the second leading cause of vision loss resulting from retinal vascular disorders. Over 1 million U.S. residents, predominantly above the age of 60, are affected by this condition, which can trigger severe and sudden vision loss.
For updates on similar health-related news, visit rttnews.com
